27m
CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference
CorMedix (NASDAQ:CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company’s focus on expanding its pipeline while integrating the recently acquired Melinta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results